CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

About CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CBAY
  • CUSIP: N/A
  • Web:
  • Market Cap: $158.14 million
  • Outstanding Shares: 28,752,000
Average Prices:
  • 50 Day Moving Avg: $4.21
  • 200 Day Moving Avg: $3.21
  • 52 Week Range: $1.15 - $5.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.21
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.79 million
  • Price / Sales: 33.01
  • Book Value: $0.32 per share
  • Price / Book: 17.19
  • EBIDTA: ($20,410,000.00)
  • Return on Equity: -259.66%
  • Return on Assets: -100.73%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 2.28%
  • Quick Ratio: 2.28%
  • Average Volume: 332,634 shs.
  • Beta: 2.05
  • Short Ratio: 1.9

Frequently Asked Questions for CymaBay Therapeutics (NASDAQ:CBAY)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc. (NASDAQ:CBAY) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.07. The firm had revenue of $4.79 million for the quarter. View CymaBay Therapeutics' Earnings History.

Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?

4 brokers have issued 1 year price objectives for CymaBay Therapeutics' shares. Their forecasts range from $6.50 to $8.00. On average, they anticipate CymaBay Therapeutics' share price to reach $7.17 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.

What are analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (4/3/2017)
  • 2. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
  • 3. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a drop in short interest during the month of June. As of June 15th, there was short interest totalling 367,834 shares, a drop of 32.6% from the May 31st total of 545,881 shares. Based on an average daily trading volume, of 315,066 shares, the short-interest ratio is currently 1.2 days. Currently, 1.5% of the shares of the stock are short sold.

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:

  • Robert James Wills Ph.D., Chairman of the Board
  • Sujal Shah, Interim President, Interim Chief Executive Officer, Chief Financial Officer
  • Charles A. McWherter Ph.D, Senior Vice President, Chief Scientific Officer
  • Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
  • Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance
  • Pol F. Boudes M.D., Chief Medical Officer
  • Robert Booth Ph.D., Director
  • Caroline Loewy, Director
  • Evan A. Stein M.D. Ph.D., Director
  • Paul F. Truex, Director

Who owns CymaBay Therapeutics stock?

CymaBay Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (3.65%), Vanguard Group Inc. (2.86%), Boxer Capital LLC (2.70%), Omega Fund Management LLC (1.05%), Renaissance Technologies LLC (0.81%) and Geode Capital Management LLC (0.59%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Emster Kurt Von, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, TFS Capital LLC, Acadian Asset Management LLC and ClariVest Asset Management LLC. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Emster Kurt Von, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy CymaBay Therapeutics stock?

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CymaBay Therapeutics stock can currently be purchased for approximately $5.50.

MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.17 (30.30% upside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/23/2017Oppenheimer Holdings Inc.Initiated CoverageOutperform$8.00HighView Rating Details
3/27/2017HC WainwrightReiterated RatingBuy$6.00 -> $7.00HighView Rating Details
3/24/2017Piper Jaffray CompaniesBoost Price TargetOverweight$5.00 -> $6.50HighView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 6/29/2015 forward)


Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings History by Quarter for CymaBay Therapeutics (NASDAQ CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.27)($0.20)$4.79 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.28)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.31)($0.25)ViewListenView Earnings Details
8/9/2016Q2($0.32)($0.30)ViewN/AView Earnings Details
5/11/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015Q1 2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.46)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.48)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
2017 EPS Consensus Estimate: ($0.81)
2018 EPS Consensus Estimate: $0.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.28)($0.28)($0.28)
Q2 20172($0.29)($0.25)($0.27)
Q3 20172($0.22)($0.20)($0.21)
Q4 20172($0.21)$0.12($0.05)
Q1 20181($0.28)($0.28)($0.28)
Q2 20181$0.48$0.48$0.48
Q3 20181$0.35$0.35$0.35
Q4 20181($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)


Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 36.87%
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.00View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CymaBay Therapeutics (NASDAQ:CBAY)
Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
DateHeadline logoCymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality ... - Nasdaq - June 27 at 9:26 PM logoCymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance - June 26 at 4:48 PM logoQ2 2017 Earnings Estimate for CymaBay Therapeutics Inc. Issued By Oppenheimer Holdings (CBAY) - June 26 at 7:08 AM logoCymaBay Therapeutics Inc. (CBAY) Expected to Announce Earnings of -$0.25 Per Share - June 23 at 10:20 PM logoCymaBay Therapeutics Inc. (CBAY) Given Average Rating of "Buy" by Brokerages - June 23 at 11:32 AM logoCymaBay Therapeutics Inc. (CBAY) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc. - June 23 at 9:06 AM logoOppenheimer Starts CymaBay Therapeutic (CBAY) at Outperform - - June 22 at 4:25 PM logoToday's Research Report Coverage on Biotech Stocks -- Jaguar Animal Health, Biostage, Cymabay Therapeutics, and ... - PR Newswire (press release) - June 15 at 4:41 PM logoCymaBay Therapeutics Inc. (CBAY) Sees Significant Decline in Short Interest - June 14 at 7:08 AM logoCymaBay Therapeutics Inc. (CBAY) Lifted to Hold at ValuEngine - June 11 at 9:34 PM logo-$0.25 Earnings Per Share Expected for CymaBay Therapeutics Inc (CBAY) This Quarter - May 30 at 6:16 PM logoCymaBay Therapeutics Inc (CBAY) Issues Quarterly Earnings Results - May 12 at 12:56 PM logoBRIEF-Cymabay Therapeutics files for potential mixed shelf offering of up to $100 mln - May 11 at 9:49 PM logoCymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q1 2017 Results - Earnings Call Transcript - May 11 at 9:49 PM logoInvestor Network: CymaBay Therapeutics, Inc. to Host Earnings Call - May 11 at 4:46 PM logoCymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 11 at 4:46 PM logoCymaBay Therapeutics Inc (CBAY) Expected to Announce Earnings of -$0.27 Per Share - May 4 at 11:40 PM logoCymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11 - May 4 at 4:17 PM logoCymaBay Therapeutics (CBAY) Receives News Impact Rating of -0.39 - May 4 at 9:17 AM logoCymaBay Therapeutics (CBAY) Receiving Somewhat Critical Media Coverage, Analysis Finds - May 1 at 2:46 PM logoCymaBay Therapeutics (CBAY) Earns Media Impact Score of 0.13 - April 25 at 12:38 PM logoCymaBay Therapeutics (CBAY) Earns Daily Media Impact Rating of -0.12 - April 18 at 1:38 PM logoCymaBay Therapeutics (CBAY) Earns Coverage Optimism Rating of 0.57 - April 15 at 7:30 AM logo Analysts Expect CymaBay Therapeutics Inc (CBAY) Will Announce Earnings of -$0.27 Per Share - April 13 at 10:24 PM logoCymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 - April 13 at 4:17 PM logoCymaBay Therapeutics Inc (CBAY) Downgraded by Zacks Investment Research - April 3 at 5:43 PM logoCymaBay Therapeutics to Present at Two Investor Conferences in April - March 30 at 4:36 PM logoCymaBay Therapeutics Inc (CBAY) Price Target Raised to $6.50 at Piper Jaffray Companies - March 30 at 10:16 AM logoCYMABAY THERAPEUTICS, INC. Financials - March 29 at 4:32 PM logoCymaBay Therapeutics (CBAY) CEO Harold Van Wart to Retire - - March 29 at 12:28 PM logoCymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. - March 29 at 12:28 PM logo8:01 am CymaBay Therapeutics announces that Harold Van Wart will retire as CEO; Sujal Shah named as interim CEO - March 29 at 12:28 PM logoCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers - March 29 at 12:28 PM logoCymaBay Therapeutics Inc (CBAY) Price Target Raised to $7.00 at HC Wainwright - March 27 at 7:36 PM logoPiper Jaffray Companies Raises CymaBay Therapeutics Inc (CBAY) Price Target to $6.50 - March 24 at 11:38 AM logoAfter-Hours Earnings Report for March 23, 2017 : MU, GME, KBH, ENV, OXM, SCVL, UPLD, SPWH, CBAY, NBY, VSTM ... - Nasdaq - March 24 at 2:36 AM logoQ4 2016 CymaBay Therapeutics Inc Earnings Release - Time Not Supplied - March 23 at 4:33 PM logoCymaBay Reports Fourth Quarter and Year End 2016 Financial Results - March 23 at 4:33 PM logoCymaBay Therapeutics Inc (CBAY) Scheduled to Post Quarterly Earnings on Thursday - March 22 at 7:34 AM logoResearch Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx ... - PR Newswire (press release) - March 18 at 5:25 AM logoWill Cymabay Therapeutics (CBAY) Continue to Surge Higher? - March 15 at 4:29 PM logoCymaBay Therapeutics to Present at Two Investor Conferences in March - March 9 at 4:45 PM logoProgenics Pharmaceuticals (PGNX) in Focus: Stock Gains 8.3% - February 28 at 9:16 AM logoCan The Uptrend Continue for Cymabay Therapeutics (CBAY)? - February 14 at 4:52 PM logoCerner's EHR Platform to Enhance Health Care at San Juan NGO - February 13 at 4:46 PM logo5 Breakout Stocks for Superior Returns - February 10 at 3:47 PM logoCymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher - February 9 at 4:28 PM logoCymaBay Therapeutics (CBAY) Prices 5.2M Offering of Common Stock at $1.93/Share - - February 3 at 4:24 PM logoCymaBay Therapeutics (CBAY) Prices 5.2M Offering of Common Stock at $1.93/Share - February 2 at 4:25 PM logoCymaBay Announces Pricing of Public Offering of Common Stock - February 2 at 4:25 PM



CymaBay Therapeutics (CBAY) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by Staff